Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P 1 receptor modulator, in the first-in-human study

British Journal of Clinical Pharmacology

Volumn 76, Issue 6, 2013, Pages 888-896

  Brossard, Patrick ^a   Derendorf, Hartmut ^b   Xu, Jian ^b   Maatouk, Haidar ^c   Halabi, Atef ^c   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c CRS Clinical Research Services Kiel GmbH   (Germany)

Author keywords

pharmacodynamics; pharmacokinetics; ponesimod; S1P1 receptor modulator; safety and tolerability; total lymphocyte count

Indexed keywords

HYDROCORTISONE; PONESIMOD;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE DISEASE; BODY TEMPERATURE; BRADYCARDIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAM; FATIGUE; FOOD DRUG INTERACTION; FORCED EXPIRATORY VOLUME; HEART RATE; HERPES SIMPLEX; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; IC 50; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL HISTORY; NORMAL HUMAN; PHYSICAL EXAMINATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; VERTIGO; VOMITING;

PHARMACODYNAMICS; PHARMACOKINETICS; PONESIMOD; S1P1 RECEPTOR MODULATOR; SAFETY AND TOLERABILITY; TOTAL LYMPHOCYTE COUNT;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, LYSOSPHINGOLIPID; THIAZOLES; YOUNG ADULT;

EID: 84883062704     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12129     Document Type: Article

References (37)

1. Tanaka T, Ebisuno Y, Kanemitsu N, Umemoto E, Yang BG, Jang MH, Miyasaka M,. Molecular determinants controlling homeostatic recirculation and tissue-specific trafficking of lymphocytes. Int Arch Allergy Immunol 2004; 134: 120-134.
2. Cyster JG,. Homing of antibody secreting cells. Immunol Rev 2003; 194: 48-60.
3. Cyster JG,. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005; 23: 127-159.
4. Brinkmann V,. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007; 115: 84-105.
5. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG,. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005; 309: 1735-1739.
6. Alvarez SE, Milstien S, Spiegel S,. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab 2007; 18: 300-307.
7. Chun J,. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002; 54: 265-269.
8. Ishii I, Fukushima N, Ye X, Chun J,. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004; 73: 321-354.
9. Meyer zu Heringdorf D, Jakobs KH,. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 2007; 1768: 923-940.
10. Alexander SP, Mathie A, Peters JA,. Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 2011; 164: (Suppl. 1): S1-324.
11. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG,. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
12. Rose NR, MacKay IR,. The Autoimmune Diseases, 4th edn. San Diego, CA: Elsevier Academic Press, 2006.
13. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, Chiba K,. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005; 2: 439-448.
14. Brinkmann V,. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009; 158: 1173-1182.
15. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW,. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140.
16. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L,. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
17. Budde K, Schmouder RL, Brunkhorst R, Nashan B, Lucker PW, Mayer T, Choudhury S, Skerjanec A, Kraus G, Neumayer HH,. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002; 13: 1073-1083.
18. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G,. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol 2004; 57: 586-591.
19. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, Mills S, Nomura N, Rosen H, Rosenbach M, Shei GJ, Singer II, Tian M, West S, White V, Xie J, Proia RL, Mandala S,. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004; 309: 758-768.
20. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H,. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279: 13839-13848.
21. Gon Y, Wood MR, Kiosses WB, Jo E, Sanna MG, Chun J, Rosen H,. S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. Proc Natl Acad Sci U S A 2005; 102: 9270-9275.
22. Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, Gatfield J, Hess P, Kohl C, Mangold C, Mathys B, Menyhart K, Muller C, Nayler O, Scherz M, Schmidt G, Sippel V, Steiner B, Strasser D, Treiber A, Weller T,. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 2010; 53: 4198-4211.
23. Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, Kohl C, Steiner B, Clozel M,. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 2011; 337: 547-556.
24. Khasnis A, Gokula RM,. Romberg's test. J Postgrad Med 2003; 49: 169-172.
25. Gibaldi M, Perrier D,. Pharmacokinetics. New York: Dekker, 1982.
26. De Rosa SC,. Multicolor immunophenotyping: human mature immune system. Methods Cell Biol 2004; 75: 577-594.
27. Beal SL, Sheiner LB, Boeckmann AJ,. NONMEM Users Guides. San Francisco, CA: NONMEM Project Group, University of California at San Francisco, 1998.
28. Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ,. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol 2003; 43: 1216-1227.
29. Stark JG, Werner S, Homrighausen S, Tang Y, Krieg M, Derendorf H, Moellmann H, Hochhaus G,. Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide. J Pharmacokinet Pharmacodyn 2006; 33: 441-459.
30. Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J,. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/ pharmacokinetics UK joint working group. Drug Inf J 1995; 29: 1039-1048.
31. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, Calmels T,. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 2002; 50: 661-670.
32. Schmouder R, Serra D, Wang Y, Kovarik JM, Dimarco J, Hunt TL, Bastien MC,. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol 2006; 46: 895-904.
33. Boxenbaum H,. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201-227.
34. Mahmood I,. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 2007; 59: 1177-1192.
35. Jones HM, Parrott N, Jorga K, Lave T,. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006; 45: 511-542.
36. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T,. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004; 44: 532-537.
37. Carandente F, Angeli A, De Vecchi A, Dammacco F, Halberg F,. Multifrequency rhythms of immunological functions. Chronobiologia 1988; 15: 7-23.